Table 4. Studies of Cancer Treatment by Infection of Patients With NDVa
| Reference Citation(s) | Type of Study | NDV Strain | Type of Cancer | No. of Patients: Enrolled; Treated; Controlb | Strongest Benefit Reportedc | Concurrent Therapyd | Level of Evidence Scoree |
| [39] | Phase II trial | MTH-68 | Various advanced | 59; 33; 26, placebo | Improved overall survival | No | 2A |
| [44] | Phase I trial | PV701 | Various advanced | 79; 79; None | Partial tumor regression, 8 patients | Unknown | 3iiiDiii |
| [46] | Phase I/II | HUJ | Glioblastoma multiforme, recurrent | 14 (phase I–6; phase II–8); 11 (phase I–6, phase II–5); 0 | 1 transient (3 mo) complete response, all other patients had progressive disease | None | 3iiiDiii |
| [38] | Case series | MTH-68 | Various advanced | 4; 4; None | Complete tumor regression, 2 patients | Yes | 4 |
| [47] | Selected case series | MTH-68/H | Gliomas, high-grade | 4; 4; 0 | Radiographically documented responses and long survival with improved symptomatology | Various | 4Diii |
| [45] | Phase I | PV701 | Various | 16; 16; 0 | Improved patient tolerability with two-step desensitization | None | N/A |
| [48] | Case report | MTH-68/H | Anaplastic astrocytoma | 1; 1; 0 | Partial response | Valproic acid | N/A |
| [40] | Case report | 73-T | Advanced cervical | 1; 1; None | Partial tumor regression | No | None |
| [41] | Anecdotal report | MTH-68 | Various metastatic | 3; 3; None | Tumor regression | Unknown | None |
| [42] | Case report | MTH-68 | Glioblastoma multiforme | 1; 1; None | Partial tumor regression | Yes | None |
| [43] | Case report | Hickman | Acute myeloid leukemia | 1; 1; None | Partial response | Yesf | None |
| mo = month; No. = number. | |||||||
| aSee text and the NCI Dictionary of Cancer Terms for additional information and definition of terms. | |||||||
| bNumber of patients treated plus number of patients control may not equal number of patients enrolled; number of patients enrolled = number of patients initially recruited/considered by the researchers who conducted a study; number of patients treated = number of patients who were given the treatment being studied AND for whom results were reported; historical control subjects are not included in number of patients enrolled. | |||||||
| cThe strongest evidence reported that the treatment under study has anticancer activity or otherwise improves the well being of cancer patients. | |||||||
| dChemotherapy, radiation therapy, hormonal therapy, or cytokine therapy given/allowed at the same time as virus treatment. | |||||||
| eFor information about levels of evidence analysis and an explanation of the level of evidence scores, see Levels of Evidence for Human Studies of Cancer Complementary and Alternative Medicine. | |||||||
| fThis patient was treated with chemotherapy and five other types of virus in addition to NDV. |
References
- Csatary LK, Moss RW, Beuth J, et al.: Beneficial treatment of patients with advanced cancer using a Newcastle disease virus vaccine (MTH-68/H). Anticancer Res 19 (1B): 635-8, 1999 Jan-Feb. [PUBMED Abstract]
- Csatary LK, Eckhardt S, Bukosza I, et al.: Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detect Prev 17 (6): 619-27, 1993. [PUBMED Abstract]
- Cassel WA, Garrett RE: Newcastle disease virus as an antineoplastic agent. Cancer 18 (7): 863-8, 1965.
- Csatary LK: Viruses in the treatment of cancer. Lancet 2 (7728): 825, 1971. [PUBMED Abstract]
- Csatary LK, Bakács T: Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma. JAMA 281 (17): 1588-9, 1999. [PUBMED Abstract]
- Wheelock EF, Dingle JH: Observations on the repeated administration of viruses to a patient with acute leukemia. A preliminary report. N Engl J Med 271(13): 645-51, 1964.
- Pecora AL, Rizvi N, Cohen GI, et al.: Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 20 (9): 2251-66, 2002. [PUBMED Abstract]
- Laurie SA, Bell JC, Atkins HL, et al.: A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization. Clin Cancer Res 12 (8): 2555-62, 2006. [PUBMED Abstract]
- Freeman AI, Zakay-Rones Z, Gomori JM, et al.: Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 13 (1): 221-8, 2006. [PUBMED Abstract]
- Csatary LK, Gosztonyi G, Szeberenyi J, et al.: MTH-68/H oncolytic viral treatment in human high-grade gliomas. J Neurooncol 67 (1-2): 83-93, 2004 Mar-Apr. [PUBMED Abstract]
- Wagner S, Csatary CM, Gosztonyi G, et al.: Combined treatment of pediatric high-grade glioma with the oncolytic viral strain MTH-68/H and oral valproic acid. APMIS 114 (10): 731-43, 2006. [PUBMED Abstract]
